OC counsels Creo Medical on €24.8m Albyn Medical acquisition
Osborne Clarke has counselled UK-based Creo Medical on its acquisition of European healthcare company Albyn Medical for €24.8 million
An international team of lawyers from Osborne Clarke has advised UK-based Creo Medical Group on the acquisition of Albyn Medical, a Spanish headquartered manufacturer and distributor of gastroenterology, urology and endoscopy products, for an equity value of €24.8 million. The agreement also included a performance-related payment of up to €2.7m, payable over the next two years in cash.
The acquisition provides Creo with Albyn Medical’s extensive sales, service, logistics, production and export capability, providing a direct route-to-market for Creo’s full suite of CE marked GI advanced energy devices. It also adds a highly complementary product range to the company’s portfolio while expanding the GI product suite and providing an opportunity for it to enter the urology market.
Osborne Clarke’s Spain team was led by Barcelona office Commercial partner David Miranda (pictured) along with Lawyers Sara Barona and Pilar Díaz.